Leveraged & Inverse Channel 3 ETFs to Access a Changing Pharmaceutical Industry By Ben HernandezAugust 16, 2021
Beyond Basic Beta Channel Alzheimer’s Drug Cost Pushes Pharmaceutical Prices Back Into the Spotlight By Tom LydonAugust 5, 2021
Beyond Basic Beta Channel Artificial Intelligence Set to Transform the Pharmaceutical Industry By Ben HernandezJune 1, 2021
Beyond Basic Beta Channel Pharma Goes Beyond the Vaccine. ‘PPH’ on the Verge of More Advances By Ben HernandezMarch 4, 2021
ETF Education channel Biopharma Here to Stay: The Long-Term Case for the PBE ETF By Tom LydonJanuary 20, 2021
Innovative ETFs Channel Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021 By Max ChenDecember 31, 2020
Nasdaq Investment Intelligence Channel Beyond the Vaccine: The Long Runway for Health and Pharmaceutical ETFs By Tom LydonNovember 25, 2020
Beyond Basic Beta Channel Pharma Sector Steps up as a Portfolio Prescription By VanEckNovember 22, 2020
Nasdaq Investment Intelligence Channel Some Good Deals Are Available in Pharmaceuticals ETFs By Tom LydonSeptember 15, 2020
Nasdaq Investment Intelligence Channel A Power Pharmaceuticals ETF to Consider By Tom LydonJuly 27, 2020
Beyond Basic Beta Channel Assessing Political Outcomes for Pharmaceuticals ETFs By Tom LydonJuly 21, 2020
Beyond Basic Beta Channel Expect Pharmaceuticals M&A Activity to Rebound After COVID-19 Eases By Tom LydonApril 17, 2020
Core Equity Channel Big Pharma Could Lift The SPDR Healthcare ETF in 2020 By Tom LydonDecember 13, 2019
Beyond Basic Beta Channel Pharma ETFs Boosted After Senate Rejects House Drug Pricing Plan By Todd ShriberSeptember 23, 2019
Innovative ETFs Channel Potential Peanut Allergy Treatment Gives Pharma Company A Boost By Ian YoungSeptember 11, 2019
Innovative ETFs Channel AbbVie, Allergan Deal Puts Spotlight on Pharmaceutical ETFs By Max ChenJune 25, 2019
